Mega Lifesciences Future Growth

Future criteria checks 2/6

Mega Lifesciences is forecast to grow earnings and revenue by 14.7% and 4.7% per annum respectively. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be 24.3% in 3 years.

Key information

14.7%

Earnings growth rate

14.3%

EPS growth rate

Pharmaceuticals earnings growth	16.9%
Revenue growth rate	4.7%
Future return on equity	24.3%
Analyst coverage	Good
Last updated	15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

SET:MEGA - Analysts future estimates and past financials data (THB Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	17,681	2,709	2,584	2,942	6
12/31/2025	16,611	2,518	2,399	2,759	7
12/31/2024	16,004	2,244	2,244	2,673	6
9/30/2024	15,882	1,846	1,693	1,966	N/A
6/30/2024	15,685	1,999	2,400	2,667	N/A
3/31/2024	15,718	2,017	1,915	2,166	N/A
12/31/2023	15,716	1,993	1,633	1,926	N/A
9/30/2023	15,442	1,919	2,297	2,583	N/A
6/30/2023	15,693	2,042	1,773	2,035	N/A
3/31/2023	15,634	2,081	1,798	2,077	N/A
12/31/2022	15,727	2,242	1,684	1,997	N/A
9/30/2022	15,116	2,338	1,327	1,596	N/A
6/30/2022	15,061	2,292	1,852	2,091	N/A
3/31/2022	14,724	2,227	1,800	2,025	N/A
12/31/2021	14,172	1,947	2,567	2,727	N/A
9/30/2021	14,395	1,878	2,302	2,474	N/A
6/30/2021	13,775	1,607	2,289	2,485	N/A
3/31/2021	12,809	1,406	1,932	2,178	N/A
12/31/2020	12,613	1,393	1,374	1,629	N/A
9/30/2020	12,168	1,348	1,487	1,815	N/A
6/30/2020	11,642	1,288	1,122	1,508	N/A
3/31/2020	11,655	1,205	1,271	1,707	N/A
12/31/2019	11,164	1,139	954	1,495	N/A
9/30/2019	10,950	1,163	468	1,406	N/A
6/30/2019	10,712	1,136	275	1,163	N/A
3/31/2019	10,569	1,203	-158	657	N/A
12/31/2018	10,284	1,206	158	910	N/A
9/30/2018	10,147	1,183	429	747	N/A
6/30/2018	9,937	1,175	N/A	929	N/A
3/31/2018	9,829	1,178	N/A	1,150	N/A
12/31/2017	9,624	1,113	N/A	927	N/A
9/30/2017	9,514	1,023	N/A	967	N/A
6/30/2017	9,282	945	N/A	1,081	N/A
3/31/2017	8,968	873	N/A	1,237	N/A
12/31/2016	8,828	795	N/A	1,250	N/A
9/30/2016	8,514	771	N/A	1,174	N/A
6/30/2016	8,226	756	N/A	920	N/A
3/31/2016	8,115	703	N/A	764	N/A
12/31/2015	7,966	696	N/A	609	N/A
9/30/2015	7,775	675	N/A	825	N/A
6/30/2015	7,862	634	N/A	803	N/A
3/31/2015	7,851	598	N/A	581	N/A
12/31/2014	7,749	548	N/A	614	N/A
9/30/2014	7,620	474	N/A	406	N/A
6/30/2014	7,422	516	N/A	416	N/A
3/31/2014	7,226	567	N/A	473	N/A
12/31/2013	7,055	624	N/A	466	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEGA's forecast earnings growth (14.7% per year) is above the savings rate (2%).

Earnings vs Market: MEGA's earnings (14.7% per year) are forecast to grow slower than the TH market (16.8% per year).

High Growth Earnings: MEGA's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEGA's revenue (4.7% per year) is forecast to grow slower than the TH market (6.6% per year).

High Growth Revenue: MEGA's revenue (4.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MEGA's Return on Equity is forecast to be high in 3 years time (24.3%)

Mega Lifesciences Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies